HRAS
HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
Overview
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Recognised by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.
CIViC holds 24 clinical evidence items and 2 assertions across 12 variants, naming Vemurafenib, Selumetinib, Cetuximab and Erlotinib and others. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes genetic literature 0.79, clinical 0.16, affected pathway 0.90, literature 0.98, genetic association 0.86, somatic mutation 0.97, animal model 0.43). IntOGen calls it a driver in 23 cohorts (23 activating, 0 loss-of-function), covering Angiosarcoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma and others. In OnCo, 1 product record names it (JYP0015).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
- 1 · What it is
HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
- 2 · What goes wrong in cancer
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
- 3 · How drugs use it
No product in this corpus aims at HRAS yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:5173 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01112 (protein name, function text, keywords and locations (REST API)); CIViC gene HRAS (24 evidence items, 2 assertions, 12 variants; diseases: Skin Squamous Cell Carcinoma, Cancer, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma, Head And Neck Cancer and 4 more (GraphQL API, CC0)); Open Targets ENSG00000174775 (association with cancer (MONDO_0004992) 0.90; per-cancer scores at or above 0.5: urinary bladder cancer 0.79, head and neck squamous cell carcinoma 0.66, sarcoma 0.67, thyroid cancer 0.77, neuroendocrine neoplasm 0.64, skin cancer 0.54 (GraphQL API, CC0)); IntOGen HRAS (driver in 23 cohorts (Act 23, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Recognised by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. Location: Cell membrane; Golgi apparatus; Golgi apparatus membrane; Nucleus (UniProt). Locus 11p15.5 (HGNC).
- Bladder & urothelial cancer: Open Targets association 0.79 with urinary bladder cancer (MONDO_0001187); CIViC evidence names this disease
- Thyroid cancer: Open Targets association 0.77 with thyroid cancer (MONDO_0002108); CIViC evidence names this disease
- Sarcomas: Open Targets association 0.67 with sarcoma (MONDO_0005089)
- Head and neck squamous cell carcinoma: Open Targets association 0.66 with head and neck squamous cell carcinoma (MONDO_0010150); CIViC evidence names this disease
- Neuroendocrine tumours: Open Targets association 0.64 with neuroendocrine neoplasm (MONDO_0019496)
- Prostate cancer: IntOGen driver in 4 cohorts (PRAD, PROSTATE)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.16; IntOGen calls it an activating (Act) driver in 23 cohorts; CIViC holds 24 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Skin Squamous Cell Carcinoma; Follicular Thyroid Carcinoma.
Latest papers
topQuery for this target: (TITLE:"HRAS" OR ABSTRACT:"HRAS" OR TITLE:"HRas proto-oncogene, GTPase" OR ABSTRACT:"HRas proto-oncogene, GTPase" OR TITLE:"GTPase HRas" OR ABSTRACT:"GTPase HRas" OR TITLE:"HRAS1" OR ABSTRACT:"HRAS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HRAS, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCHEK2
Shares Thyroid cancer, Sarcomas (soft tissue, bone, GIST), Breast cancer (all types), CIViC.
- TargetCDKN1B
Shares Thyroid cancer, Neuroendocrine tumours, Breast cancer (all types), CIViC.
- TargetSTAG2
Shares Thyroid cancer, Sarcomas (soft tissue, bone, GIST), Bladder & urothelial cancer, Breast cancer (all types).
- TargetEPHB2
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Prostate cancer.
- TargetEPHB4
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.
- TargetEPHA3
Shares Thyroid cancer, Neuroendocrine tumours, Breast cancer (all types), IntOGen.
- TargetSMAD3
Shares Thyroid cancer, Breast cancer (all types), CIViC, IntOGen.
- TargetRB1
Shares Bladder cancer (KEGG map), Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST), Bladder & urothelial cancer.